- NEWS FEATURE
- Clarification 07 April 2022
The quest to prevent MS — and understand other post-viral diseases
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 per month
cancel any time
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Get just this article for as long as you need it
Prices may be subject to local taxes which are calculated during checkout
Nature 603, 784-786 (2022)
Updates & Corrections
Clarification 07 April 2022: An earlier version of this story stated that Katherine Luzuriaga is the lead investigator on the mRNA-1189 trial. She is, in fact, the lead investigator only for the UMass Chan part of the trial.
Bjornevik, K. et al. Science 375, 296–301 (2022).
Lanz, T. V. et al. Nature 603, 321–327 (2022).
Cohen, J. I. Clin. Transl. Immunol. 4, e32 (2015).
Luzuriaga, K. & Sullivan, J. L. N. Engl. J. Med. 362, 1993–2000 (2010).
Messick, T. E. et al. Sci. Transl. Med. 11, eaau5612 (2019).
Lebrun-Frenay, C. et al. Ann. Neurol. 88, 407–417 (2020).
Douaud, G. et al. Nature https://doi.org/10.1038/s41586-022-04569-5 (2022).